French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products. The report highlights the safety and effectiveness of INTERCEPT platelets during the first full year of routine use. “The new hemovigilance data published by ANSM underscores the clinical utility and the safety